Malignant mixed müllerian tumor of the uterus in a patient taking raloxifene

Noah A. Goldman; Maria M. De Los Angeles; Joan G. Jones; Gary L. Goldberg

doi:10.1097/01.AOG.0000160480.55365.a8

Malignant mixed müllerian tumor of the uterus in a patient taking raloxifene

Noah A. Goldman, Maria M. De Los Angeles, Joan G. Jones, Gary L. Goldberg

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

BACKGROUND: Uterine malignant mixed mesodermal tumor is a rare variant of uterine cancer. Data suggest that tamoxifen is involved in the pathogenesis. We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator. CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention. Diagnosis had been delayed secondary to sampling of the other uterine horn. CONCLUSION: There may be an association between raloxifene and the development of malignant mixed mesodermal tumor. Special attention should be paid when attempting to sample the endometrium in patients with müllerian abnormalities.

Original language	English (US)
Pages (from-to)	1278-1280
Number of pages	3
Journal	Obstetrics and gynecology
Volume	105
Issue number	5 II
DOIs	https://doi.org/10.1097/01.AOG.0000160480.55365.a8
State	Published - May 1 2005

ASJC Scopus subject areas

Obstetrics and Gynecology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/01.AOG.0000160480.55365.a8

Cite this

@article{e8b79c56b60449efaf89aae743d31ca2,

title = "Malignant mixed m{\"u}llerian tumor of the uterus in a patient taking raloxifene",

abstract = "BACKGROUND: Uterine malignant mixed mesodermal tumor is a rare variant of uterine cancer. Data suggest that tamoxifen is involved in the pathogenesis. We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator. CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention. Diagnosis had been delayed secondary to sampling of the other uterine horn. CONCLUSION: There may be an association between raloxifene and the development of malignant mixed mesodermal tumor. Special attention should be paid when attempting to sample the endometrium in patients with m{\"u}llerian abnormalities.",

author = "Goldman, {Noah A.} and {De Los Angeles}, {Maria M.} and Jones, {Joan G.} and Goldberg, {Gary L.}",

year = "2005",

month = may,

day = "1",

doi = "10.1097/01.AOG.0000160480.55365.a8",

language = "English (US)",

volume = "105",

pages = "1278--1280",

journal = "Obstetrics and gynecology",

issn = "0029-7844",

publisher = "Lippincott Williams and Wilkins",

number = "5 II",

}

TY - JOUR

T1 - Malignant mixed müllerian tumor of the uterus in a patient taking raloxifene

AU - Goldman, Noah A.

AU - De Los Angeles, Maria M.

AU - Jones, Joan G.

AU - Goldberg, Gary L.

PY - 2005/5/1

Y1 - 2005/5/1

N2 - BACKGROUND: Uterine malignant mixed mesodermal tumor is a rare variant of uterine cancer. Data suggest that tamoxifen is involved in the pathogenesis. We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator. CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention. Diagnosis had been delayed secondary to sampling of the other uterine horn. CONCLUSION: There may be an association between raloxifene and the development of malignant mixed mesodermal tumor. Special attention should be paid when attempting to sample the endometrium in patients with müllerian abnormalities.

AB - BACKGROUND: Uterine malignant mixed mesodermal tumor is a rare variant of uterine cancer. Data suggest that tamoxifen is involved in the pathogenesis. We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator. CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention. Diagnosis had been delayed secondary to sampling of the other uterine horn. CONCLUSION: There may be an association between raloxifene and the development of malignant mixed mesodermal tumor. Special attention should be paid when attempting to sample the endometrium in patients with müllerian abnormalities.

UR - http://www.scopus.com/inward/record.url?scp=20844447333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20844447333&partnerID=8YFLogxK

U2 - 10.1097/01.AOG.0000160480.55365.a8

DO - 10.1097/01.AOG.0000160480.55365.a8

M3 - Article

C2 - 15863610

AN - SCOPUS:20844447333

SN - 0029-7844

VL - 105

SP - 1278

EP - 1280

JO - Obstetrics and gynecology

JF - Obstetrics and gynecology

IS - 5 II

ER -

Malignant mixed müllerian tumor of the uterus in a patient taking raloxifene

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this